Posted by Michael Wonder on 18 Jan 2023
Paratek Pharmaceuticals announces inclusion of Nuzyra (omadacycline) in China’s National Reimbursement Drug List (NRDL)
18 January 2023 - National Healthcare Security Administration adds Nuzyra to NRDL for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Paratek Pharmaceuticals today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous formulation of Nuzyra (omadacycline) to the country’s National Reimbursement Drug List for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, resulting in millions of patients gaining access to the broad spectrum, once daily antibiotic.
